Japan market size · Drug class

Long-acting (basal) insulins in Japan

持効型インスリン

The prescription value of Long-acting (basal) insulins (5 molecules) in Japan was an estimated ¥18.4 billion in FY2024. Value changed -6.7% year on year and -7.1% a year on average over the last three years. The largest molecule is インスリンデグルデク（遺伝子組換え） (54%). In addition, 1 combination products totalled ¥1.1 billion.

¥18.4bnValue FY2024 (single agents)

-6.7%Year on year

-7.1%3-year average growth

Trend and molecules

Hover or tap a year for the values.

Trend (single agents)

Prescription value (est.)YoY upYoY down

By molecule (FY2021 = 100)

Molecules in this class

インスリンデグルデク（遺伝子組換え）インスリンデグルデク（遺伝子組換え）インスリングラルギン（遺伝子組換え）インスリングラルギン（遺伝子組換え）インスリングラルギン（遺伝子組換え）［インスリングラルギン後続１］インスリングラルギン（遺伝子組換え）［インスリングラルギン後続１］インスリンデテミル（遺伝子組換え）インスリンデテミル（遺伝子組換え）インスリングラルギン（遺伝子組換え）［インスリングラルギン後続２］インスリングラルギン（遺伝子組換え）［インスリングラルギン後続２］インスリングラルギン（遺伝子組換え）・リキシセナチドインスリングラルギン（遺伝子組換え）・リキシセナチド

All markets

Need the numbers behind the lines?

Year-by-year values for each related drug, company-level shares, and Excel downloads are available to our clients in Japan. Tell us what you are looking at and we will reply in English.

About the data

Values are estimates: prescription volumes from Japan's NDB Open Data (Ministry of Health, Labour and Welfare; excluding public-expense claims), FY2015–FY2024, multiplied by the NHI reimbursement price of each product at the time of each release (nominal). All strengths and brands of the molecule are combined. Japanese fiscal years run from April to March (FY2024 = April 2024 – March 2025). Until FY2023 the NDB lists only the top products by volume in each therapeutic class; years in which a molecule is not listed are shown as “not listed”. Growth rates compare the same products in consecutive years and are chained; the 3-year rate is not shown when the base year value is below one tenth of the latest year. The comparison with related drugs is an index with FY2021 = 100. Supply: MHLW, as of 2026-09-27.